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Mena deficiency delays tumor progression and
decreases metastasis in polyoma middle-T
transgenic mouse mammary tumors
Evanthia T Roussos1*, Yarong Wang1, Jeffrey B Wyckoff1,2, Rani S Sellers3, Weigang Wang1, Jiufeng Li4,
Jeffrey W Pollard4, Frank B Gertler5*, John S Condeelis1,2*
Abstract
Introduction: The actin binding protein Mammalian enabled (Mena), has been implicated in the metastatic
progression of solid tumors in humans. Mena expression level in primary tumors is correlated with metastasis in
breast, cervical, colorectal and pancreatic cancers. Cells expressing high Mena levels are part of the tumor
microenvironment for metastasis (TMEM), an anatomical structure that is predictive for risk of breast cancer
metastasis. Previously we have shown that forced expression of Mena adenocarcinoma cells enhances invasion and
metastasis in xenograft mice. Whether Mena is required for tumor progression is still unknown. Here we report the
effects of Mena deficiency on tumor progression, metastasis and on normal mammary gland development.
Methods: To investigate the role of Mena in tumor progression and metastasis, Mena deficient mice were
intercrossed with mice carrying a transgene expressing the polyoma middle T oncoprotein, driven by the mouse
mammary tumor virus. The progeny were investigated for the effects of Mena deficiency on tumor progression via
staging of primary mammary tumors and by evaluation of morbidity. Stages of metastatic progression were
investigated using an in vivo invasion assay, intravital multiphoton microscopy, circulating tumor cell burden, and
lung metastases. Mammary gland development was studied in whole mount mammary glands of wild type and
Mena deficient mice.
Results: Mena deficiency decreased morbidity and metastatic dissemination. Loss of Mena increased mammary
tumor latency but had no affect on mammary tumor burden or histologic progression to carcinoma. Elimination of
Mena also significantly decreased epidermal growth factor (EGF) induced in vivo invasion, in vivo motility,
intravasation and metastasis. Non-tumor bearing mice deficient for Mena also showed defects in mammary gland
terminal end bud formation and branching.
Conclusions: Deficiency of Mena decreases metastasis by slowing tumor progression and reducing tumor cell
invasion and intravasation. Mena deficiency during development causes defects in invasive processes involved in
mammary gland development. These findings suggest that functional intervention targeting Mena in breast cancer
patients may provide a valuable treatment option to delay tumor progression and decrease invasion and
metastatic spread leading to an improved prognostic outcome.
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Introduction
Metastasis is the primary cause of death from breast
cancer, the most common form of cancer affecting
women in the United States, and the second leading
cause of cancer related deaths in women around the
world [1]. Tumor cells make use of different cellular
processes to execute the steps of metastasis: invasion,
intravasation, extravasation, tumor cell dissemination,
extravasation and growth of distant metastases [1]. Use
of multiphoton intravital microscopy enabled the obser-
vation of migration of tumor cells across the endothelial
barrier into blood vessels at sites containing at least one
peri-vascular macrophage [2]. This led to the develop-
ment of an in vivo invasion assay used to capture live,
invasive and metastatic tumor cells from the primary
tumor for analysis [3]. Furthermore, the study of inva-
sion, intravasation and metastasis using both methods
has shown the involvement of a paracrine loop between
macrophages and tumor cells that secrete EGF or colony
stimulating factor-1 (CSF1), respectively [3,4].
Expression profiling of invasive tumor cells captured
using the in vivo invasion assay revealed the upregula-
tion of several key cytoskeletal regulatory proteins
involved in cell motility [5-10]. Mena was among the
proteins that comprise what was termed the Invasion
Signature and has since been shown to be upregulated
in rat, mouse and human mammary tumors and to cor-
relate with metastatic risk [5,10-12]. Evaluation of high
risk primary and metastatic cervical, colorectal and pan-
creatic cancers have also shown enhanced expression of
Mena as compared to low risk cases [11,13-15]. Mena
has been used in the development of a prognostic mar-
ker of hematogenous metastasis called TMEM (Tumor
Micro-Environment for Metastasis), shown to be asso-
ciated with risk of metastasis in breast cancer patients
independently of traditional prognostic markers [12].
Mena (also known as ENAH-enabled homolog) is a
member of the Ena/VASP family of actin-regulatory pro-
teins that function in multiple different cell types to regu-
late cell morphology and motility [16,17]. Similar to other
Ena/VASP proteins, Mena regulates the geometry and
assembly of actin filament networks through binding of
profilin and both G- and F-actin, the ability to promote
filament elongation through monomer delivery and anti-
capping activity [18,19], and the ability to reduce the den-
sity of Arp2/3-mediated branching [17,19-22].
There are at least two alternative splice variants of
Mena in tumor cells; the two best characterized iso-
forms are Mena invasive (INV), found exclusively in inva-
sive tumor cells and Mena11a, found in primary tumor
cells but lost in invasive cells [5]. Recent studies in
rodent models show an increase in metastasis upon
forced expression of Mena and MenaINV without any
affect on primary tumor growth [23]. This increase in
metastasis was found to arise from increased EGF-
induced invasion, tumor cell protrusion and matrix
degradation activity by invadopodia [23].
To determine if Mena is required for tumor progres-
sion and metastasis, we used previously generated Mena
Null mice [24] and intercrossed them with transgenic
mice carrying the mammary tumor virus (MMT-V)-
polyoma middle T antigen (PyMT) [25]. Mammary
tumors growing in the PyMT expressing mice go
through distinct morphologic stages of tumor progres-
sion comparable to progression of human breast disease
and develop spontaneous metastases following disease
progression [26]. Thus, they provide an excellent model
for the investigation of the role of Mena in tumor pro-
gression and metastasis.
All Mena isoforms are completely eliminated in Mena
homozygous mice and reduced in heterozygote mice
[24]. Mena homozygous mutant (Mena Null) mice are
fully viable, but slightly smaller than their littermates
until adulthood [24]. Mena Null mice exhibit a variety
of subtle nervous system defects such as misrouted axon
fiber tracts in the cortex including the major brain com-
missures, the corpus callosum and hippocampus; these
phenotypes all become more severe and other structures
such as the optic nerve and spinal nerves become dis-
rupted when the other two Ena/VASP paralogs are
deleted along with Mena [24,27-29]. The invertebrate
orthologs of Mena have been shown to function down-
stream of axonal guidance receptors DCC and Robo
[30,31], which have also been implicated in the morpho-
genesis of the mammary gland [32]. Little, however, is
known about the role of Mena in the developing mam-
mary gland. Since tumor cells are thought to acquire
the ability to invade surrounding stroma via a re-awa-
kening of developmental processes [33-35], the investi-
gation of Mena in mammary gland development could
provide insight into Mena’s role in tumor cell invasion
and dissemination in mammary tumors.
We provide evidence that, in Mena Null mice, overall
tumor burden is unaffected while tumor latency is
increased and mortality is decreased. Additionally, we
show that in Mena Null mice, invasion, intravasation,
motility and metastasis are significantly decreased. Defi-
ciency of Mena also leads to decreased terminal end
bud formation and branching during mammary gland
development but has no affect on ductal growth. These
findings provide important insight into the functions of
Mena during tumor progression and metastasis and pro-
vide evidence that these malignant processes could
represent the revival of Mena’s role in processes resem-
bling mammary gland development within the primary
tumor. Our study provides evidence that inhibition of
Mena activity may be a useful approach to prevention of
metastasis.
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Materials and methods
Animal models and assays for tumor progression
All studies were carried out using protocols approved by
the Albert Einstein College of Medicine Animal Care
and Use Committee. GFP labeled macrophages were
recreated on the FVB Tg(Csf1r-eGFP)1 background
using an identical construct and strategy as published
[36]. CFP labeled mammary carcinoma cells were gener-
ated on the FVB background by co-injection of Tg
(MMTV-iCRE)1jwp together with Tg(PCAG-loxp-CAT-
stop-loxp-CFP) plasmids by conventional methods in the
Albert Einstein Transgenic Mouse Facility and were
similar to previously described mice [37]. These mice
were then crossed with previously described Mena het-
erozygotes [24]. Germline transmission of alleles was
verified by PCR using the following primer sequences:
MMTV-iCRE-PCAG-loxp-CAT-stop-loxp-CFP: (forward)
CAG GGC CTT CTC CAC ACC AGC, (reverse) CTG
GCT GTG AAG ACC ATC, cFMS-GFP: (forward) TCA
TTC CAG AAC CAG AGC, (reverse) TGC TCA GGT
AGT GGT TGT CG. Primers sequences used to identify
transmission of the disrupted Mena allele can be pro-
vided upon request. All PyMT mouse tumors were pal-
pated beginning at six weeks of age and measured by
calipers to monitor tumor formation.
Orthotopic PyMT xenograft tumors were derived from
subcutaneous injection of 1 × 106 CFP-PyMT primary
tumor cells FAC sorted from PyMT/Mena wild type
(WT), PyMT/Mena heterozygote (Het) and PyMT/Mena
homozygous (Null) mice into the mammary gland of
five-to-seven-week-old female severe combined immune
deficient (SCID) mice purchased from the National Can-
cer Institute [3]. The purpose of this study was to con-
firm that the PyMT tumor cells injected into SCID mice
(all with an identical genotype) that were also wild type
for Mena, would grow and metastasize in a manner
similar to that identified in their parental mouse strain.
Once tumors reached 2 cm3 in size (approximately 8 to
12 weeks after injection) animals were used for the indi-
cated experiments.
Orthotopic MTLn3 xenograft tumors were derived
from mammary gland injection of 1 × 106 MTLn3 rat
adenocarcinoma cells or MTLn3 cells forced to express
Mena, into SCID mice [23,38]. Once tumors reached
2 cm3 in size (approximately four weeks after injection)
animals were used for the indicated experiments.
MTLn3-Mena expressing cells expressed the Mena pro-
tein four-fold over endogenous levels to mimic Mena
over-expression previously identified in invasive tumor
cells [8]. For a full description of cell line derivation,
clonal selection and culturing of these cell lines see
reference [23].
Staging of mammary tumors from PyMT mice was
done according to criteria previously described [26].
Tumors growing in PyMT mice have been shown to
progress at different rates, for example at 10 weeks of
age it is common to find some tumors that are hyper-
plastic while other tumors from the same animal have
already progressed to invasive carcinoma [26]. Addition-
ally, even within the same tumor there can be regions of
that tumor that are normal and regions that show varied
histological progression [26]. Therefore, we staged mul-
tiple different tumors and different regions within each
tumor from each animal evaluated (15 to 20 of each
PyMT Mena WT, Het and Null mice) at 10 weeks of
age to ensure identification of the most progressed his-
tology. Tumor stage was finally determined and classi-
fied based on the most advanced histological stage
identified, (that is, a mouse with regions of hyperplasia
and invasive carcinoma either within the same tumor or
in different tumors, the stage of progression was
reported as carcinoma). Evaluation of staging was per-
formed by double blind. To determine the number of
tumor cells in circulation, blood was drawn from the
right ventricle of the heart in anesthetized mice harbor-
ing at least one tumor that was 2 cm3 in size as pre-
viously described [39]. Single tumor cells were counted
seven days after plating; all cells counted were CFP
positive.
Metastasis characterization and Immunohistochemistry (IHC)
Mammary tumors, mammary glands and lungs were
fixed in 10% buffered formalin and routinely embedded
in paraffin. Spontaneous lung metastases (>2 mm) were
evaluated in formalin fixed, paraffin embedded and
hematoxylin and eosin stained lung tissue. To quantify
lung metastases, eight 10-μm paraffin sections were cut
at 50 μm apart and placed on slides for further staining.
Lung metastases were counted in all five lung lobes.
Metastases spanning multiple sections were only
counted in the first section where they were identified.
Evaluation of metastases was performed double blind.
Fixed mammary tumors matched for age and tumor
stage were stained for vasculature using an antibody
against CD-34 (1:100) (Invitrogen, Carlsbad, CA, USA),
five 200× fields were analyzed in five animals per geno-
type to determine differences in vascular density. Fixed
mammary glands stained with F4/80 at 1:50 (a gift from
Dr. Richard Stanley) to identify macrophages as pre-
viously described [40]. F4/80 has been shown to specifi-
cally identify mononuclear mouse macrophages [41] and
has been used in IHC and FAC sorting to identify
macrophages by many different groups [42-44]. Evalua-
tion of the expression of Mena in mammary glands was
evaluated in formalin fixed, paraffin embedded tissue
from six-week-old PyMT negative Mena WT, Het and
Null mice. Primary antibody against Mena was used at
(1:1000) [45], antigen retrieval was done using buffered
Roussos et al. Breast Cancer Research 2010, 12:R101
http://breast-cancer-research.com/content/12/6/R101
Page 3 of 16
citrate, and DAB (Invitrogen) was used to visualize
staining, hematoxylin was used as a counterstain. All
slides were imaged using Zeiss AxioObserver.Z1 5×
DIC1, EC Plan-Neofluar 10×/0.3 Ph1, EC Plan-Neofluar
20×/0.5 Ph2 M27, EC Plan-Neofluar 40×/0.75 Ph2 M27,
EC Plan-neofluar 63×/1.4 Oil and an AxioCamHR3. All
objectives and microscopes were manufactured by Zeiss,
Oberkochen, Germany.
Whole mount mammary gland preparation and staining
The evaluation of mammary gland maturation was per-
formed on five of each PyMT negative Mena WT, Het,
and Null mice at 6 and 10 weeks of age. Following
euthanasia, the fourth abdominal mammary glands were
surgically removed and placed on a glass slide and fixed
and stained as previously described [40]. Ductal length,
terminal end bud counts and branching were deter-
mined as previously described [40]. To determine nor-
malized macrophages/TEB area, macrophages were
counted around individual TEBs and the area of each of
these TEBs was measured. Data represent the number
of macrophages/TEB area in pixels and are normalized
to a constant area. To determine the average number of
macrophages/area, macrophages were counted within an
identical fixed area either surrounding TEBs or in
stroma (without any TEBs). Data represent raw counts
of macrophages within this fixed area. A minimum of
10 fields were counted from five mice per genotype for
these experiments.
Intravital imaging
Intravital multiphoton imaging was performed on 15 of
each PyMT Mena WT, Het and Null mice as described
previously using a 20× 1.95 NA water immersion objec-
tive with correction lens [46,47]. Time-lapse movies
were analyzed for frequency of motility in three dimen-
sions and through time using ImageJ [48]. A cell move-
ment event was defined as a translocation ≥1 cell
diameter within a field, a field is defined as 100 μm
*512 × 512* minute. To acquire this size volume took
two minutes. All movies of cell movements were 30
minutes in duration.
In vivo invasion assay
The in vivo invasion assay was performed in 5 to 10
mice per condition as previously described [49]. Briefly,
needles were held in place by a micromanipulator
around a single mammary tumor of an anesthetized
mouse. Needles contained a mixture of Matrigel™,
25 nM EGF, buffer and EDTA. After four hours of cell
collection the contents of the needles were extruded.
Cells were then stained with DAPI and counted using
an Olympus IX70 inverted microscope with a 10× NA
0.30 objective.
Statistical analysis
Statistical significances were determined using unpaired,
two-tailed Student’s t-tests assuming equal variances
and an alpha level of 0.05 for all experiments unless
otherwise indicated. For lung metastasis and assays eval-
uating the number of circulating tumor cells in the
blood non-parametric the Mann Whitney Wilcoxon
rank sum test was used. For Kaplan-Meier plots Log-
rank (Mantel-Cox) t-test was performed.
Results
Deficiency of Mena increases tumor latency and
decreases morbidity
We sought to determine whether MMTV-PyMT-driven
mammary tumor formation is affected by the absence of
Mena. Investigation of mammary tumor onset showed
that Mena deficiency increased tumor latency signifi-
cantly (Figure 1A) compared to Mena WT and Het
mice (P-value = <0.0001). Mice heterozygous for Mena
showed a slight decrease in tumor latency as compared
to WT mice (Figure 1A) (P-value = 0.02).
Mice were considered ‘not moribund’ until they either
died or had to be euthanized due to illness or immobili-
zation as a result of their tumor burden. Mena Null
mice had a later tumor onset than did the Mena WT or
Het mice (Figure 1A) and survived longer than either
Mena WT or Het mice that reached the tumor size
limit or died (P-value = 0.01, 0.03 respectively) (Figure
1B). There were no significant differences in morbidity
between Mena WT and Het mice (P-value = 0.91) (Fig-
ure 1B).
In those mice with tumors at 10 weeks of age, Mena
Null mice had significantly fewer tumors/animal (Figure
1C). Additionally, tumor growth was significantly
decreased in Mena Null mice that were growing tumors
at both 8 and 10 weeks of age. These results reflect the
increased tumor latency in Mena Null mice observed
between 60 and 100 days as shown in Figure 1A. Inter-
estingly, as Mena Null mice aged, the number of tumors
per animal as well as tumor growth were not signifi-
cantly different as compared to Mena WT or Het mice
(Figure S1 in Additional file 1 Figure 1D).
Deficiency of Mena slows progression to invasive
carcinoma
Distinct stages of tumor progression have been identi-
fied in PyMT-generated mammary tumors and have
been shown to correlate with the benign, in situ prolif-
erative lesions, and invasive carcinomas seen in humans
[26]. We used a classification system that identifies dis-
tinct histopathologic changes and represents morpholo-
gical events of tumor progression from benign to
malignant: hyperplasia, adenoma and invasive carcinoma
[26]. Characteristics used to determine stage of tumor
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progression include appearance of acini, individual
epithelial cell morphology and structure of the mam-
mary glands (Figure 2A, B and Figure S2 in Additional
file 1). Mammary glandular hyperplasia is characterized
by densely packed lobules and hyperplastic acini lined
by epithelial cells which generally retain their normal
cuboidal appearance (Figure 2Bi, ii, iii, Figure S2A in
Additional file 1). Some acini may be filled with epithe-
lial cells, but are not notably expanded in size
(Figure 2B, black arrows). Mammary gland adenomas
are characterized by marked epithelial proliferation that
fills and markedly expands the acini and ducts addition-
ally; the cells have slight cellular atypia (Figure 2B iv, v,
vi, Figure S2B in Additional file 1). Mammary carcino-
mas are characterized by solid sheets of cells with little
or no acinar architecture remaining (Figure 2B vii, viii,
ix, Figure S2C in Additional file 1). The neoplastic cells
have cellular and nuclear atypia, numerous mitotic fig-
ures, and frequently demonstrate invasion into the sur-
rounding stroma (Figure 2B vii, viii, ix, Figure S2C in
Additional file 1). Histologic evaluations of tumors
revealed these features and were identified in all PyMT
mice regardless of Mena genotype (Figure 2B).
Staging of tumors from PyMT Mena WT, Het and
Null mice at 10 weeks of age showed that by 10 weeks
80% of Mena WT and Het mice had at least one tumor
or parts of a tumor that had progressed to carcinoma
(Figure 2C). Neither Mena WT nor Het mice had
tumors that could be classified as hyperplastic due to
the presence of more advanced stages of progression
within these tumors (Figure 2C). Twenty percent of
both genotypes of mice had tumors staged as adenoma
Figure 1 Deficiency of Mena increases tumor latency and decreases morbidity. A. Percent of mice without palpable tumors at the given
age. N >100 mice/genotype. P-values by Log-rank (Mantel-Cox) test: Mena WT vs. Het = 0.02, Mena WT vs. Null <0.0001, Mena Het vs. Null
<0.0001. B. Kaplan Meir curve measuring percentage of mice from each genotype that are not moribund (mice that have not yet developed
tumors or mice that have small tumors that have not immobilized them). N = 12 to 25 mice/genotype. P-values by Log-rank (Mantel-Cox) test:
Mena WT vs. Het = 0.44, Mena WT vs. Null = 0.01, Mena Het vs. Null = 0.05. C. Average number of tumors per mouse at 10 weeks of age. N =
25 mice/genotype. Error bars indicate SEM. P-values by student’s t-test are listed above columns. D. Average tumor size at given age. Tumors
measured with digital calipers. For each genotype N = 5 mice/given age. Error bars indicate SEM. P-values by student’s t-test for Mena WT vs.
Mena Null at 8 weeks = 0.033, at 10 weeks = 0.034, all other P-values > 0.05.
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Figure 2 Deficiency of Mena slows progression to invasive carcinoma. A. Immunohistochemistry of normal mammary acinus from PyMT
mouse at 10 weeks of age stained with Hematoxylin and Eosin. B. Immunohistochemistry of mammary gland tumors from PyMT Mena WT, Het
and Null mice at 10 weeks of age stained with Hematoxylin and Eosin. Mammary glandular hyperplasia (i, ii, iii); Acini are not notably expanded
in size (arrow). Mammary gland adenomas (iv, v, vi). Mammary carcinomas (vii, viii, ix). Scale bar = 100 μm. High magnification images showing
some of the characteristics used to stage tumors are shown in Figure S2 in Additional file 1. C. Percent of mice with hyperplastic changes (white
bar), adenoma (purple bar), and carcinoma (red bar). N = number of mice used for each genotype (listed below the x-axis).
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(Figure 2C). Interestingly, 21% of Mena Null mice had
mammary tumors that were staged as hyperplastic, 43%
that were staged as adenoma and only 36% that were
staged as carcinoma (Figure 2C). Additionally, we
observed the presence of normal tissue in all animals
(Mena WT, Het and Null) regardless of tumor stage.
Thus, deficiency of Mena delays but does not prevent
progression to malignancy (Figure 2C).
Deficiency of Mena dampens EGF-induced in
vivo invasion and motility
An early step in metastatic progression is invasion out
of the primary tumor and into the surrounding stroma
[1]. Therefore, we used an in vivo invasion assay to
score EGF induced invasion [49]. We found that Mena
Null mice had significantly decreased in vivo invasion as
compared to Mena WT and Het mice (Figure 3A). The
requirement of Mena for invasion observed above is
consistent with the overexpression of Mena isoforms
which leads to increased invasion (Figure S3 in Addi-
tional file 1) and [23].
Another measure of invasive potential is cell migration
within and out of the primary tumor into the stroma.
Prior work showed increased motility in orthotopic
mammary tumors derived from injection of MTLn3 rat
adenocarcinoma cells forced to express Mena [23]. We
used intravital multiphoton microscopy to investigate the
effect of Mena deficiency on tumor cell motility in vivo
in PyMT Mena WT, Het and Null mice. The average
number of tumor cells moving per field was significantly
decreased in Mena Null mice as compared to both Mena
WT and Het mice (Figure 3B, C Additional files 2, 3, 4).
Deficiency of Mena decreased intravasation and
metastasis to the lung
The next step of metastasis, intravasation into blood
vessels, was measured by evaluation of the number of
circulating tumor cells in a clonogenic assay since in
PyMT mammary tumors, the number of circulating
tumor cells has been correlated with intravasation [2].
In fact, Mena Null mice had significantly fewer circulat-
ing tumor cells as compared to Mena WT and Het
mice, which were not significantly different from each
other (Figure 4A).
Previous studies show that the forced expression of
Mena in orthotopic mammary tumors derived from
tumor cell injection into the mammary gland of SCID
mice, significantly increased metastasis to the lung [23].
Thus, we hypothesized that deficiency of Mena would
reduce the number of metastases to the lung. Evaluation
of the number of lung metastases in PyMT from Mena
WT, Het and Null mice, whose tumors were stage
matched for carcinoma, showed that Mena Null mice
had significantly fewer lung metastases as compared to
Mena WT and Het mice (Figure 4B). Additionally, there
were no differences observed in appearance (size and
location) of lung metastases (Figure 4C).
These findings suggest that deficiency of Mena signifi-
cantly decreases metastasis by affecting invasion, intra-
vasation and motility within the primary tumor.
Mena Null xenografts show decreased intravasation
and lung metastasis
Mena is expressed in both stromal and tumor cells, rais-
ing the formal possibility that loss of Mena reduced
metastasis through an effect on the tumor microenvir-
onment rather than the tumor cells. To determine if the
altered metastasis in Mena deficient animals resulted
from defects intrinsic to the tumor cells, we isolated
tumor cells from Mena Null or WT animals and trans-
planted them into SCID mice. The mammary glands of
SCID mice were injected with Mena WT or Null tumor
cells isolated by FAC sorting from the respective PyMT
mammary tumors. Mice growing orthotopic tumors
derived from injection of Mena Null cells showed signif-
icantly decreased numbers of circulating tumor cells
(Figure 5A) and lung metastases (Figure 5B). For addi-
tional validation of this methodology we used intravital
multiphoton microscopy to compare the primary tumor
morphology of tumors derived from injection of PyMT
tumor cells versus that of spontaneously growing
tumors from PyMT animals. Surprisingly, we found that
the xenograft tumors had a similar morphology to the
spontaneously growing tumors from PyMT animals
(Figure 5C). This observation suggests that this method
provides a reliable recapitulation of the PyMT tumor.
Overall, these data support the conclusions that defi-
ciency of Mena in tumor cells is responsible for the sig-
nificant decrease in intravasation and lung metastasis
observed in PyMT Mena Null mice.
Given that a deficiency of Mena had such a profound
effect on intravasation as compared to Mena WT mice
(Figures 4A and 5A) we investigated if there were any
differences in vascular density. Immunohistochemical
staining of blood vessels was performed on primary
tumors from PyMT Mena WT and Null mice and we
found that Mena Null mice had significantly fewer ves-
sels located throughout the tumors as compared to
tumors from Mena WT mice (Figure S4A in Additional
file 1). Immunohistochemical staining of blood vessels
was also performed on primary tumors from xenograft
mice derived from injection of tumor cells isolated from
PyMT Mena WT and Null mice and we found that
there was no difference in vascular density in Mena
Null tumors as compared to Mena WT (Figure S4B in
Additional file 1). Lastly, immunohistochemical staining
of blood vessels performed on primary tumors from
xenograft mice derived from injection of MTLn3 and
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MTLn3-Mena overexpressing tumor cells revealed no
difference in vascular density in Mena overexpressing
tumors as compared to MTLn3 control (Figure S4C in
Additional file 1). Hence, the large difference in intrava-
sation score observed in these different cases is not
explained by differences in microvessel density alone.
Mena deficiency reduces terminal end bud formation and
branching during mammary gland development
Post-natal mammary gland development is commenced
by formation and outgrowth of multilaminate epithelial
structures called terminal end buds (TEB) (black arrows,
Figure 6Aiii) [34]. These bifurcate to give a primary
branched structure that then attains secondary branches
along the primary ductal tree (black arrow heads, Figure
6Aiii). During this process of branching morphogenesis,
the TEBs invade the surrounding fatty stroma in
response to signals from cells in the surrounding micro-
environment [34]. Given that Mena is expressed in nor-
mal mammary ductal epithelial cells (Figure S5 in
Additional file 1), and that Mena deficiency leads to
decreased in vivo invasion in PyMT tumor bearing mice
Figure 3 Deficiency of Mena dampens EGF-induced in vivo invasion and motility. A. In vivo invasion assay of PyMT mice with given Mena
genotype. White bars indicate average number of tumor cells that invaded in the absence of EGF, gray bars indicate average number of tumor
cells that invaded in the presence of 25 nM EGF. P-values listed above bars. N = 12 assays/genotype/condition. Error bars indicate SEM.
B. Average number of cells moving/field quantified from intravital imaging of PyMT Mena WT, Het and Null mice. 30 to 50 fields analyzed from
10 mice per genotype. Error bars = SEM. C. Multiphoton microscopy of tumor cells moving within the primary tumors of PyMT Mena WT, Het
and Null mice. Images taken at 60× over the course of 30 minutes. Yellow outlines indicate cells that are moving (refer to Additional files 2, 3, 4).
White = CFP tumor cells, Green = GFP macrophages, Black = tumor stroma and vasculature. Scale bar = 50 μm.
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(Figure 3A), we sought to determine if the deficiency of
Mena affects invasive stages of normal mammary gland
development. Thus, we investigated TEB formation,
branching and ductal growth in mammary glands of
otherwise normal mice that do not express the PyMT
oncogene. Examination of mammary gland whole
mounts from Mena WT, Het and Null mice at 6 weeks
(Figure 6Ai) and 10 weeks (Figure 6Aii) of age showed a
significant decrease in the number of TEBs in Mena
Null mice as compared to Mena WT and Het (Figure
6Ai, ii and 6B). Additionally, investigation of these same
whole mounts showed significantly decreased ductal
branching in Mena Null as compared to Mena WT and
Het mice at six weeks (Figure 6C). However, at
10 weeks ductal branching in Mena Null mice was not
significantly different from Mena WT (Figure 6C).
Given that Mena expression does not affect tumor
growth [23], we hypothesized that duct length would be
unaffected and indeed we found it was unaffected by
Mena deficiency at both 6 and 10 weeks of age (Figure
6D). Interestingly, a deficiency of Mena delays but does
not prevent development of TEBs and ductal branching
(Figure 6B, C) similar to the delay seen during tumor
progression in PyMT Mena Null mice (Figure 2). These
data suggest that Mena’s role in developmental pro-
cesses may be similar to its role during tumor progres-
sion. Another interesting finding is that Mena Het mice
have significantly increased TEB formation at 10 weeks
as compared to Mena WT (Figure 6B). Given that dif-
ferent aspects of breast development have been shown
to play a role in breast disease [50-52], it is possible that
the changes observed in TEB formation in Mena Null
Figure 4 Deficiency of Mena decreases intravasation and metastasis to the lungs. A. Average number of circulating tumor cells in the
blood of PyMT animals staged with carcinoma. Number of mice used of each genotype listed within bars. P-values listed above bars. Error bars
indicate SEM. B. Average number of spontaneous lung metastases in PyMT animals staged with carcinoma. Number of mice used of each
genotype listed within bars. P-values listed above bars. Error bars indicate SEM. C. Immunohistochemistry of lung metastases (indicated with
black arrows) from the lungs of Mena WT, Het and Null mice. Images in the left column were taken at 50× (Scale bar = 200 μm), images in the
right hand column were taken at 100× (Scale bar = 100 μm).
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and Mena Het mice could be correlated with tumor
latency; a decrease in TEB formation in Mena Null mice
could lead to increased tumor latency (Figure 1A) slow-
ing progression (Figure 2C), while an increase in TEB
formation in Mena Het mice could lead to decreased
latency (Figure 1A) and thus enhanced progression.
Interactions between epithelial and stromal cells con-
tribute to the development of the epithelial ductal tree
during mammary gland development [34,53,54], specifi-
cally, macrophages play a role in tissue remodeling dur-
ing development and in normal tissue homeostasis
[40,55]. Additionally, studies have shown that elimina-
tion of macrophages in PyMT mice significantly
decreases lung metastasis [56] and EGF induced in vivo
invasion [3]. Previously, we have shown that expression
of Mena and MenaINV in tumor cells sensitizes cells to
stimulation by EGF during macrophage mediated in vivo
invasion [23] and transendothelial migration [57]. We
have also shown that increased in vivo invasion and
streaming tumor cell motility in MenaINV expressing
tumor cells is dependent on macrophages [57]. We
hypothesize that expression of Mena enhances tumor
cell/macrophage paracrine interactions and that elimina-
tion of Mena will significantly decrease macrophage
dependent processes. Previous studies suggest that
macrophages are required for the formation of TEBs
and branching of associated ducts [40]. Therefore, given
that Mena Null mice show a defect in terminal end bud
formation and branching, we measured the number of
macrophages surrounding the TEBs at six weeks of age.
The number of macrophages was evaluated for a stan-
dardized TEB area to account for differences in TEB
size (Figure 7B). Macrophage density was also counted
in a given area surrounding TEBs and in the stroma
(not surrounding TEB) to determine if macrophage
recruitment to TEB was specifically affected (Figure 7C).
We found that there are fewer macrophages per TEB
area in Mena Null mice vs. Mena WT (Figure 7A, B).
Additionally, the number of macrophages recruited to
TEB is significantly reduced as compared the number of
stromal macrophages in Mena Null vs. Mena WT mice
(Figure 7C). These data confirm that a deficiency of
Figure 5 Tumors from orthotopic transplantation of Mena Null cells show decreased intravasation and lung metastasis. A. Average
number of circulating tumor cells in the blood of SCID mice injected with PyMT Mena WT, and Null tumor cells. N = 10 mice/genotype. P-
values listed above bar. Error bars indicate SEM. B. Average number of spontaneous lung metastases in SCID mice injected with PyMT Mena WT,
and Null tumor cells. N = 10 mice/genotype. P-values listed above bar. Error bars indicate SEM. C. Multiphoton microscopy of primary tumors of
SCID mice injected with PyMT Mena WT, and Null tumor cells. Images taken at 20×. Blue = CFP tumor cells, Black = tumor stroma and
vasculature. Scale bar = 50 μm.
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Figure 6 Deficiency of Mena alters mammary gland development. A. Representative images of mammary gland whole mounts from PyMT
Mena WT, Het and Mena Null mice at 6 weeks (i) and 10 weeks (ii) of age. Scale bar = 1 cm. Enlarged area of six-week whole mount mammary
glands shown in iii. In iii = whole mount mammary gland from PyMT Mena WT mouse. Black arrows point to examples of terminal end buds.
Black arrowheads point to examples of branches. Images taken at 10×. B. Quantification of terminal end buds from mammary gland whole
mounts. Examples of terminal end buds counted are shown in Figure 6A by the black arrows. N = 5 animals per genotype at each time point.
P-values listed above bars. Error bars = SEM. C. Quantification of mammary duct branching quantified under 5×. Examples of branches counted
are shown in Figure 6A iii by the black arrowheads. N = 5 fields/animal, 10 animals per genotype. P-values listed above bars. Error bars = SEM.
D. Quantification of the length of the three longest ducts from mammary gland whole mounts. N = 10 animals per genotype. P-values listed
above bars. Error bars = SEM.
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Mena specifically leads to decreased recruitment of
macrophages around the TEBs. These results suggest
that Mena may be necessary for mammary gland differ-
entiation and could play a direct or indirect role in
macrophage mediated invasion in vivo.
Discussion
Through the use of newly developed technologies
including, high density mircroarray based expression
profiling, intravital imaging and the collection of live
invasive tumor cells from primary tumors, transiently
expressed genes, such as Mena were identified as modu-
lators of metastasis [8]. Such findings support the theory
of metastasis whereby a population of tumor cells exhi-
bits metastatic capabilities very early in tumor progres-
sion as a result of transient changes in gene expression.
The Invasion Signature is a set of transiently regulated
genes in metastatic tumor cells that control their che-
motactic and migratory behavior; Mena has been identi-
fied as a master regulator of cell motility pathways in
the Invasion Signature [8,23]. The upregulation of Mena
in rat, mouse, and human mammary tumors [5,11,12],
use of Mena in the prognostic marker TMEM [12], and
Mena’s significant role in the regulation of metastatic
progression [19,21,23], render Mena an interesting ther-
apeutic target. Our findings indicate that elimination of
Mena activity could be a useful goal for therapy of
metastatic disease.
Mena deficiency delays tumor progression and decreases
invasion, intravasation, and metastases
Our results demonstrate that loss of Mena in a trans-
genic mouse model of breast carcinoma decreases
metastatic potential due to decreased invasion and intra-
vasation. Importantly, Mena Null mice remain healthy
for longer despite their equally large tumor burden as
compared to Mena WT and Het mice. While a delay in
onset of tumor development is observed, this does not
seem to be a major contributing factor affecting the
drastic increase in survival given that Mena Null mice
still show histological progression to invasive carcinoma.
Thus, the dramatic increase in survival of Mena Null
mice is most likely associated with the significant
decrease in formation of lung metastases. We propose
Figure 7 Deficiency of Mena decreases macrophage recruitment to terminal end buds. A. Immunohistochemistry of terminal end buds of
mammary glands from PyMT Mena WT, and Null mice. Blue = h ematoxilin and brown = F4/80+ macrophages (examples identified by black
arrows). Scale bar = 50 μm. B. Quantification of macrophage number per surface unit of terminal end bud. N = 10 animals per genotype.
P-values listed above bars. Error bars = SEM. C. Quantification of the number of macrophages around terminal end buds and the number of
macrophages in surrounding stroma in 200× field in both Mena WT (white bars) and Mena Null (black bars) animals. N = 5 animals per
genotype. P-values listed above bars. Error bars = SEM.
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that the increase in tumor latency may be a result of
decreased ductal branching and TEB formation identi-
fied in Mena Null mammary gland development. Addi-
tionally, the decrease in tumor latency seen in Mena
Het animals could be attributed to the increase in TEB
identified during mammary gland development. This
phenomenon will be investigated in future studies.
Given that metastasis is responsible for the majority of
cancer related deaths [58], it is important to determine
the mechanisms involved in this process. Previous stu-
dies in PyMT mice illustrate the contribution of the
microenvironment to metastatic potential and describe a
paracrine loop whereby invasion, intravasation and
metastasis involve signaling between macrophages and
tumor cells where these cells secrete EGF and CSF1
respectively [3,4]. Our findings illustrate that a defi-
ciency in Mena leads to blunted EGF induced in vivo
invasion, intravasation and lung metastases.
Previous studies have shown that the motility of
tumor cells correlates with their ability to intravasate
and that both processes require the participation of
macrophages [3]. Multiphoton intravital microscopy is a
powerful tool used to study tumor cell behavior within
primary tumors and enables the visualization of differ-
ences in motility within the tumor microenvironment
[47]. We demonstrate that tumor cells in Mena Null
mice move significantly less than tumor cells in Mena
WT and Het mice, another contributing factor toward
decreased metastatic potential. These findings are con-
sistent with an increase in movement and velocity in
MTLn3 rat adenocarcinoma cells forced to express
Mena isoforms [23]. Additionally, given that there is no
difference in vascular density in xenograft tumors
derived from injection of Mena Null and Mena WT
cells obtained from PyMT animals or in xenografts
derived from MTLn3 Mena overexpressing cells, we
conclude that the decrease in intravasation observed in
both transgenic PyMT Mena Null mice and in Mena
Null xenograft mice is the result of a Mena deficiency in
tumor cells leading to a change in their intravasation
phenotype and is not due to changes in vascular density.
We hypothesize that the decrease in vasculature
observed in transgenic PyMT Mena Null mice is related
to the deficiency of Mena in endothelial cells and
requires further investigation.
Mena deficiency delays ductal branching and terminal
end bud formation during mammary gland development
Control of tumor cell invasion has been linked to the
reawakening and seizure of developmental programs by
malignant cells [33,35]. Our findings, that loss of Mena
decreases ductal branching and TEB formation (both
considered to be invasive processes in the developing
mammary gland), and blunts invasion during metastatic
progression, suggests that Mena’s role in developmental
invasion is recapitulated during metastatic progression.
Interestingly, during nervous system development, Ena/
VASP proteins are required for normal response to the
axon guidance factors SLIT and Netrin [30,59]. Both
SLIT and Netrin have been shown to play an important
role in mammary gland morphogenesis [32,60,61] and in
regulation of cell invasion across basement membranes
[62]. Thus, we speculate that Mena’s affects on invasion
during development and metastasis may involve SLIT
and Netrin. Future studies will evaluate this hypothesis
and determine the mechanism behind the observations
reported here. Additionally in humans, intraductal
spreading can be observed in malignant lesions classified
as ductal carcinoma in situ (DCIS) and may be related
to the process of ductal branching during development
[63,64]. Since DCIS shows no evidence of invasion into
surrounding stroma, a decrease in ductal branching in
Mena Null mice could contribute to the delay in histo-
logical tumor progression but not metastatic progres-
sion. Additionally, intraductal spreading as identified in
human cancer was not observed in the PyMT model of
invasive breast carcinoma (Rani Sellers, personal com-
munication) therefore, it will be interesting to determine
if Mena deficiency affects this phenomenon in a differ-
ent model.
Our finding that fewer macrophages are recruited to
TEBs in the developing mammary gland of Mena Null
mice, and our previous findings showing macrophage
dependent in vivo invasion, intravasation and motility of
Mena expressing cells [57], suggests that Mena is
involved in a signaling loop with macrophages during
development as well as during metastatic progression.
Additionally, macrophages lack detectable Mena expres-
sion, but they do express the related Ena/VASP family
members VASP and EVL (Unpublished observations,
FBG). Thus tumor cell/macrophage interactions, or lack
thereof, as described above, may be due to a Mena defi-
ciency in tumor cells specifically (as supported by xeno-
transplant studies described in Figure 5). Further studies
will be conducted to investigate this hypothesis.
Conclusions
Deficiency of Mena in the PyMT transgenic model of
breast carcinoma increases tumor latency and decreases
the rate of tumor progression to the histologic stage of
carcinoma. Significant reductions in EGF induced in
vivo invasion, intravasation and motility are strongly
correlated with the decrease in lung metastasis and mor-
bidity seen in Mena Null mice. This striking decrease in
metastasis is recapitulated by the implantation of Mena
Null tumor cells into a mouse host that is wild type for
Mena showing a tumor cell autonomous effect. Addi-
tionally, Mena deficiency in non-tumor bearing mice
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leads to defects in invasive stages of mammary gland
development such as terminal end bud formation and
ductal branching, raising the intriguing possibility that
Mena is part of a developmental program that is re-
activated during metastatic progression. Given that loss
of Mena is compatible with viability, we propose that
inhibition of Mena could be used as a treatment for
metastatic disease in breast cancer patients.
Additional material
Additional file 1: Figure S1: Average number of tumors per mouse
at 16 weeks of age. N = 25 mice/genotype. Error bars indicate SEM. P-
values by student’s t-test are listed above columns. Figure S2:
Imunohistochemistry images (400×) of mammary tumors from Mena WT
mice at 10 weeks of age. A. Hyperplasia: densely packed lobules and
hyperplastic acini lined by epithelial cells which generally retain their
normal cuboidal appearance. Some acini may be filled with epithelial
cells, but are not notably expanded in size. B. Adenoma: marked
epithelial proliferation which fill and expand the acini and ducts. Cells
have slight cellular atypia (box). C. Carcinomas: solid sheets of cells with
little or no acinar architecture remaining. Neoplastic cells have cellular
and nuclear atypia (box), numerous mitotic figures (arrow), and
frequently demonstrate invasion into the surrounding stroma. Figure S3:
In vivo invasion assay of tumor cells from tumors in xenograft mice
derived from injection of MTLn3 or MTLn3-Mena overexpressing cells.
Bars indicate the average ratio of: tumor cells collected in 25 nM EGF
containing needles/tumor cells collected in control needles (containing
no EGF). P-value listed above bars. N = 12 assays/genotype/condition.
Error bars indicate SEM. Figure S4: A. Average number of blood vessels in
primary tumors from PyMT Mena WT and Null mice. Error bars indicate
SEM. P values listed above bars. B. Average number of blood vessels in
xenograft primary tumors derived from injection of PyMT Mena WT and
tumor cells. Error bars indicate SEM. P values listed above bars. C.
Average number of blood vessels in xenograft primary tumors derived
from injection of MTLn3 control and MTLn3-Mena over-expressing tumor
cells. Error bars indicate SEM. P values listed above bars. Figure S5: IHC of
normal/non-tumor bearing mammary glands from Mena WT mice at 10
weeks of age stained with antibody against Mena (brown) and
counterstained with Hematoxylin (purple). Image taken at 40×. Scale bar
= 20 μm.
Additional file 2: Tumor cell motility in PyMT Mena WT mice.
Multiphoton microscopy of tumor cells moving within the primary
tumors of PyMT Mena WT mice. Images taken at 60× over the course of
30 minutes. White = CFP tumor cells, Green = GFP macrophages, Black =
tumor stroma and vasculature.
Additional file 3: Tumor cell motility in PyMT Mena Het mice.
Multiphoton microscopy of tumor cells moving within the primary
tumors of PyMT Mena Het mice. Images taken at 60× over the course of
30 minutes. White = CFP tumor cells, Green = GFP macrophages, Black =
tumor stroma and vasculature.
Additional file 4: Tumor cell motility in PyMT Mena Null mice.
Multiphoton microscopy of tumor cells moving within the primary
tumors of PyMT Mena Null mice. Images taken at 60× over the course of
30 minutes. White = CFP tumor cells, Green = GFP macrophages, Black =
tumor stroma and vasculature.
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